Tvardi Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1407553072
USD
3.89
-0.06 (-1.52%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Is Tvardi Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of March 1, 2022, Tvardi Therapeutics, Inc. is considered a risky investment due to its overvaluation indicated by a negative P/E ratio of -9.66 and EV/EBITDA of -10.10, despite a recent 1-year return of 276.26%, which is overshadowed by a long-term decline of 92.59% over the past five years.

As of 1 March 2022, the valuation grade for Tvardi Therapeutics, Inc. moved from attractive to risky, indicating a shift in perception regarding its valuation. The company appears to be overvalued, with a P/E ratio of -9.66 and an EV/EBITDA of -10.10, both of which are significantly below industry norms. The absence of a PEG ratio further complicates the valuation picture, suggesting a lack of growth potential relative to its price.<BR><BR>In comparison to its peers, Tvardi Therapeutics is underperforming; for instance, its P/E ratio is notably worse than the industry average, which typically reflects more stable companies. The stock has shown impressive returns recently, with a 1-year return of 276.26% compared to the S&P 500's 17.14%, but this is overshadowed by its long-term performance, where it has declined by 92.59% over the past five years. This stark contrast highlights the volatility and potential risks associated with investing in Tvardi Therapeutics.

Read More

Is Tvardi Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of October 1, 2023, Tvardi Therapeutics, Inc. has a bullish technical stance with moderate strength, supported by positive MACD and moving averages, and has outperformed the S&P 500 with a 1-year return of 276.26% compared to 17.14%.

As of 1 October 2023, the technical stance for Tvardi Therapeutics, Inc. is bullish with moderate strength. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and daily moving averages. The monthly MACD is mildly bullish, while the KST shows a mixed view with a mildly bearish weekly signal but bullish monthly. Dow Theory and OBV both indicate a mildly bullish stance on a weekly and monthly basis. <BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 across multiple periods, with a 1-year return of 276.26% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Risky -

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -56.06%, its profits have fallen by 0%
2

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 278 Million (Micro Cap)

stock-summary
P/E

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.24

stock-summary
Return on Equity

-999,999.00%

stock-summary
Price to Book

8.45

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-89.96%
0%
-89.96%
6 Months
-84.8%
0%
-84.8%
1 Year
-58.77%
0%
-58.77%
2 Years
-82.82%
0%
-82.82%
3 Years
-65.82%
0%
-65.82%
4 Years
-99.13%
0%
-99.13%
5 Years
-99.28%
0%
-99.28%

Tvardi Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-22.82%
EBIT Growth (5y)
12.53%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
EV to EBITDA
EV to Capital Employed
EV to Sales
PEG Ratio
NA
Dividend Yield
ROCE (Latest)
ROE (Latest)
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -100.00% vs 73.33% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 185.71% vs 36.36% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "2.60",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.90",
          "val2": "-2.40",
          "chgp": "-270.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "2.90",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "12.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4.20",
          "val2": "-4.90",
          "chgp": "185.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-928.80%",
          "chgp": "92.88%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -66.19% vs -49.88% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 40.17% vs -38.60% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.10",
          "val2": "21.00",
          "chgp": "-66.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-55.60",
          "val2": "-121.20",
          "chgp": "54.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8.50",
          "val2": "0.60",
          "chgp": "1,316.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-70.90",
          "val2": "-118.50",
          "chgp": "40.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-7,815.70%",
          "val2": "-5,794.30%",
          "chgp": "-202.14%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
2.60
-100.00%
Operating Profit (PBDIT) excl Other Income
-8.90
-2.40
-270.83%
Interest
0.00
2.90
-100.00%
Exceptional Items
12.80
0.00
Consolidate Net Profit
4.20
-4.90
185.71%
Operating Profit Margin (Excl OI)
0.00%
-928.80%
92.88%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -100.00% vs 73.33% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 185.71% vs 36.36% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
7.10
21.00
-66.19%
Operating Profit (PBDIT) excl Other Income
-55.60
-121.20
54.13%
Interest
8.50
0.60
1,316.67%
Exceptional Items
-9.80
0.00
Consolidate Net Profit
-70.90
-118.50
40.17%
Operating Profit Margin (Excl OI)
-7,815.70%
-5,794.30%
-202.14%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -66.19% vs -49.88% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 40.17% vs -38.60% in Dec 2023

stock-summaryCompany CV
About stock-summary
stock-summary
Company Coordinates stock-summary
Company Details
stock-summary
Tel:
stock-summary
stock-summary
Registrar Details